Sandbox MEN 2 epi

__NOTOC_

Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Sandbox MEN 2 epi On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox MEN 2 epi All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox MEN 2 epi
CDC on Sandbox MEN 2 epi
Sandbox MEN 2 epi in the news
Blogs on Sandbox MEN 2 epi
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Sandbox MEN 2 epi

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Prevalence

• • Worldwide, the prevalence of multiple endocrine neoplasia type 2 is 2.5 per 100,000 persons in 2010.
  • In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person.
  • MEN2 has been reported in approximately 500 to 1000 families worldwide.

• • 70-80% of all multiple endocrine neoplasia type 2 cases are MEN type 2A.

Incidence

• • In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.

Age

• It can be found in all ages.
• MEN 2B manifest in early infancy while MEN 2A and familial medullary thyroid carcinoma is found in adulthood.

Gender

• The prevalence and incidence of multiple endocrine neoplasia type 2 does not vary by gender.

Race

• The prevalence of multiple endocrine neoplasia type 2 does not vary by race.

Developed Countries

• In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person..